Pfizer continues development on twice-daily weight loss drug

Pfizer is continuing its development of a twice-daily weight loss drug danuglipron after scrapping a once-daily drug lotiglipron over liver damage concerns. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the story.